Multiple Myeloma
Conditions
Keywords
Farydak, panobinostat
Brief summary
This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.
Interventions
DRUGFarydak
non-interventional study
Sponsors
pharmaand GmbH
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing and able to provide written informed consent * At least 18 years of age * Clinical diagnosis of multiple myeloma that meets published diagnostic criteria * Initiating panobinostat within 60 days of enrollment * ECOG performance status 0-1 * Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response * Willing and able to complete the PRO questionnaire
Exclusion criteria
* Diagnosed with any B-cell malignancy other than myeloma * Estimated life expectancy \<6 months * Currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to treatment | 24 months | Looking for patient reproted response to treatment with panobinostat |
Countries
United States
Outcome results
None listed